Author of

• 20166

  +

  P1.17 - Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies (ID 703)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22845

    +

    P1.17-015 - Long Acting Octreotide plus Prednisone in Advanced Thymic Epithelial Tumors: A Real Life Clinical Experience (ID 10354)

    09:30 - 09:30  |  Author(s): E. Matano
    • Abstract

    Background:
    The effectiveness of long acting octreotide and prednisone has been already observed in some cases of advanced, heavily pretreated thymic epithelial tumors (TETs) and confirmed in small phase II study with an overall response rate of about 30-38%. Based on these reports, here we investigate the outcome of patients treated with LAR octreotide and prednisone in a real life clinical experience.
    
    Method:
    All the patients with advanced and heavily pretreated TETs, who received LAR octreotide and prednisone from January 2007 to January 2017, were included in this monocentric, retrospective analysis. As for local practice, all the patients performed OctreoScan and the treatment schedule consisted of administration of LAR octreotide (30 mg/every 28 days intramuscularly) plus prednisone 0.2 mg/kg/day until documented progressive disease. Patients characteristics, survival outcome, overall response rate and toxicity were evaluated.
    
    Result:
    26 patients (12 males and 14 females) were included in the study. The median overall survival was 88 months, which statistically correlates with histotype (thymoma vs thymic carcinoma) (p=0.0006), but no with stage disease (Masaoka-Koga IVA vs IVB) (p=0.21). The median progression free survival of 21 months, statistically correlates with stage disease (p=0.008); age at diagnosis (p=0.04) and previous surgery (p=0.04). No correlation has been found with histotype (p=0.12) and line of therapy (third vs beyond) (p=0.50). In the whole population, an overall response rate of 42% was achieved and only 2 patients, both with thymic carcinoma, showed a progressive disease. Treatment was safe and no severe side effects were registered.
    
    Conclusion:
    Our clinical real life data confirm that somatostatin analogs plus prednisone is an effective and safe treatment in advanced, heavily pretreated TETs and, despite the new available therapy options, it may be still considered in the therapeutic algorithm for obtaining a prolonged control disease.